(via NewsDirect)
The Cohort Review Committee (CRC) has reported no safety issues in the onCARlytics monotherapy lead-in study, prompting the clearance of the first cohort and the initiation of the combination arm.
The OASIS trial represents a pioneering approach in solid tumour treatment, combining a CD19-expressing oncolytic virus to prime tumours for attack by CD19-targeting therapeutics.
The trial's potential to shift the paradigm in solid tumour treatment is underlined by the promising advancements, with the combination arm set to explore the efficacy of onCARlytics in conjunction with blinatumomab.
“It’s once again a credit to our team and collaborators to see yet another study progressing positively and on schedule," Chong said. "Completion of this first monotherapy intratumoural cohort where ovarian, breast and melanoma patients were dosed paves the way for us to move into an important combination dosing with Blincyto®, where we’ll be eager to see the greater potential of onCARlytics in targeting and eradicating solid tumours."
Contact Details
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source